Vistagen Therapeutics (VTGN) Non Operating Interest Expenses (2011 - 2019)

Vistagen Therapeutics has disclosed Non Operating Interest Expenses across 9 years of filings, most recently posting -$1500.0 for Q4 2019.

• In Q4 2019, Non Operating Interest Expenses fell 183.33% year-over-year to -$1500.0; the TTM figure through Dec 2019 stood at -$14100.0 (down 283.12% YoY), while the FY2019 annual figure was $8000.0, down 10.11% from the prior year.
• Non Operating Interest Expenses came in at -$1500.0 for Q4 2019 at Vistagen Therapeutics, up from -$15400.0 in the prior quarter.
• In the past five years, Non Operating Interest Expenses ranged from a high of $755000.0 in Q2 2015 to a low of -$15400.0 in Q3 2019.
• Average Non Operating Interest Expenses over 5 years is $43100.0, with a median of $1900.0 recorded in 2016.
• Year-over-year, Non Operating Interest Expenses soared 200.0% in 2017 and plunged 631.03% in 2019.
• Over 5 years, Non Operating Interest Expenses stood at $3000.0 in 2015, then plunged by 66.67% to $1000.0 in 2016, then soared by 100.0% to $2000.0 in 2017, then slipped by 10.0% to $1800.0 in 2018, then sank by 183.33% to -$1500.0 in 2019.
• Per Business Quant data, the three most recent Non Operating Interest Expenses figures were -$1500.0 in Q4 2019, -$15400.0 in Q3 2019, and $1000.0 in Q1 2019.